{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:59:55Z","timestamp":1768874395471,"version":"3.49.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ygyno.2014.08.033","type":"journal-article","created":{"date-parts":[[2014,8,30]],"date-time":"2014-08-30T16:00:15Z","timestamp":1409414415000},"page":"349-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer"],"prefix":"10.1016","volume":"135","clinical-trial-number":[{"clinical-trial-number":"nct00532194","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00866697","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01015118","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01167712","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01610206","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01669798","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Angeles Alvarez","family":"Secord","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew B.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert I.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.08.033_bb0005","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2010.11.035","article-title":"Overview of anti-angiogenic agents in development for ovarian cancer","volume":"121","author":"Burger","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ncponc1051","article-title":"Angiogenesis as a strategic target for ovarian cancer therapy","volume":"5","author":"Spannuth","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0015","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-09-2797","article-title":"Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0020","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0025","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0030","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0035","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.lba5002","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3802\/jgo.2013.24.1.83","article-title":"Advanced ovarian cancer: what should be the standard of care?","volume":"24","author":"Goff","year":"2013","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0045","first-page":"LBA 1","article-title":"AGO-OVAR 12: a randomized placebo-controlled GCIG\/ENGOT-intergroup phase III trial of standard frontline chemotherapy+\/\u2212nintedanib for advanced ovarian cancer","volume":"23","author":"du Bois","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0050","series-title":"Presented at: the European Cancer Congress; September 27\u2013October 1, 2013; Amsterdam, Netherlands","article-title":"Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial","author":"Ledermann","year":"2013"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0055","series-title":"Presented at: the European Cancer Congress; September 27\u2013October 1, 2013; Amsterdam, Netherlands","article-title":"A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1","author":"Monk","year":"2013"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1470-2045(01)00556-3","article-title":"Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications","volume":"2","author":"Toi","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0065","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0070","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.clinbiochem.2004.01.014","article-title":"Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients","volume":"37","author":"Kassim","year":"2004","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0075","first-page":"1973","article-title":"Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer","volume":"24","author":"Li","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ygyno.2006.03.058","article-title":"Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer","volume":"103","author":"Hefler","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0085","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1158\/1078-0432.CCR-07-1888","article-title":"Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?","volume":"14","author":"Duncan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2010.08.016","article-title":"Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer","volume":"119","author":"Han","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0095","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/1078-0432.CCR-12-2535","article-title":"Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab","volume":"19","author":"Hegde","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","article-title":"Markers of response for the antiangiogenic agent bevacizumab","volume":"31","author":"Lambrechts","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0105","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ctrv.2011.06.004","article-title":"Targeting angiogenesis in ovarian cancer","volume":"38","author":"Schmitt","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0110","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1349-7006.2010.01547.x","article-title":"Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer","volume":"101","author":"Doi","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.21922","article-title":"Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis","volume":"51","author":"Johansson","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"ix81","key":"10.1016\/j.ygyno.2014.08.033_bb0120","article-title":"Biomarker (BM) results from GOG-0218, a phase 3 trial of front-line bevacizumab (BV)+chemotherapy (CT) for ovarian cancer (OC)","volume":"23","author":"Birrer","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0125","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling \u2014 in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/dbio.1997.8639","article-title":"VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane","volume":"188","author":"Oh","year":"1997","journal-title":"Dev Biol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0135","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/0008-5472.CAN-07-2572","article-title":"Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer","volume":"68","author":"Jeon","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrc863","article-title":"Lymphangiogenesis and cancer metastasis","volume":"2","author":"Stacker","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0145","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/1078-0432.CCR-10-1791","article-title":"Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer","volume":"17","author":"Jubb","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0150","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bjc.6600701","article-title":"Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma","volume":"88","author":"Yokoyama","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0155","doi-asserted-by":"crossref","first-page":"6957-6966","DOI":"10.1158\/1078-0432.CCR-13-0926","article-title":"Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)","volume":"19","author":"Nixon","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0160","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1158\/1078-0432.CCR-13-0489","article-title":"Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection","volume":"19","author":"Collinson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0165","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/ijc.24028","article-title":"Functional significance of VEGFR-2 on ovarian cancer cells","volume":"124","author":"Spannuth","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ygyno.2009.08.019","article-title":"VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion","volume":"115","author":"Wang","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0180","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1158\/1078-0432.CCR-07-0197","article-title":"Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma","volume":"13","author":"Lu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0185","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ajog.2007.12.028","article-title":"Impact of vessel maturation on antiangiogenic therapy in ovarian cancer","volume":"198","author":"Lu","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0190","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2005.01.032","article-title":"Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab\u2032, leads to fluid accumulation and is associated with increased tumor vascularized volume","volume":"23","author":"Jayson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0195","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.2006.09.0795","article-title":"Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas","volume":"25","author":"Birrer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0200","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1038\/sj.onc.1204755","article-title":"Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer","volume":"20","author":"Steele","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0205","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","article-title":"Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice","volume":"90","author":"Yoneda","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0022-4804(03)00307-X","article-title":"Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis","volume":"115","author":"Sako","year":"2003","journal-title":"J Surg Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0215","first-page":"1579","article-title":"Angiogenic protein expression in advanced epithelial ovarian cancer","volume":"3","author":"Barton","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0220","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejso.2006.07.015","article-title":"Angiopoietins in malignancy","volume":"33","author":"Bach","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0235","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1038\/sj.onc.1210288","article-title":"Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2","volume":"26","author":"Winter","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0240","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/13543784.2012.656197","article-title":"Development of novel CXCR4-based therapeutics","volume":"21","author":"Peled","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0245","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/157489212801820039","article-title":"CXCR4 inhibitors: tumor vasculature and therapeutic challenges","volume":"7","author":"de Nigris","year":"2012","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0250","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.577","article-title":"Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA. 14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer","volume":"29","author":"Aguilar-Mahecha","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0255","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.11030","article-title":"Angiogenic marker associated with resistance to neoadjuvant chemoradiotherapy in rectal cancer","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0260","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.2741\/3009","article-title":"Osteopontin as a target for cancer therapy","volume":"13","author":"Johnston","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0265","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1447-0756.2006.00403.x","article-title":"Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer","volume":"32","author":"Nakae","year":"2006","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0270","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.e14627","article-title":"The role of serum osteopontin (OPN) as a prognostic and predictive marker in patients with advanced gastric cancer","volume":"29","author":"Yazici","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0275","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.2174\/138161212802002797","article-title":"Interleukin-6\/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer","volume":"18","author":"Dijkgraaf","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0280","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","article-title":"Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials","volume":"13","author":"Tran","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0285","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.4520","article-title":"Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): results from CALGB 90206 (Alliance)","volume":"31","author":"Nixon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0290","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.4042","volume":"31","author":"Heymach","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0295","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0300","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2010.32.5944","article-title":"Phase I\/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer","volume":"29","author":"Rudin","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0305","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0315","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2013.01.006","article-title":"A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study","volume":"129","author":"Schilder","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0320","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10520290802451085","article-title":"Immunohistochemistry in the evaluation of neovascularization in tumor xenografts","volume":"83","author":"Wang","year":"2008","journal-title":"Biotech Histochem"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0325","doi-asserted-by":"crossref","first-page":"e1002875","DOI":"10.1371\/journal.pcbi.1002875","article-title":"Significance analysis of prognostic signatures","volume":"9","author":"Beck","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0330","doi-asserted-by":"crossref","first-page":"e30269","DOI":"10.1371\/journal.pone.0030269","article-title":"Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer","volume":"7","author":"Bentink","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0335","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5509","article-title":"Prognostic significance of differential expression of angiogenic genes in women with invasive high-grade serous ovarian carcinoma","volume":"31","author":"Siamakpour-Reihani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0340","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5510","article-title":"Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma","volume":"31","author":"Konecny","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1752-0509-6-3","article-title":"Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies","volume":"6","author":"Ben-Hamo","year":"2012","journal-title":"BMC Syst Biol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0350","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2014.03.564","article-title":"MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer","volume":"133","author":"Chan","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0355","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/bjc.2011.551","article-title":"The role of EZH2 in tumour progression","volume":"106","author":"Chang","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0360","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","article-title":"Regulation of tumor angiogenesis by EZH2","volume":"18","author":"Lu","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0365","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0370","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5502","article-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","volume":"32","author":"Gourley","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0375","series-title":"Presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting; May 30\u2013June 3, 2014; Chicago, IL","article-title":"Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer","author":"Winterhoff","year":"2014"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0380","author":"Ferriss"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0385","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0390","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0395","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0400","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/bjc.2011.191","article-title":"DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6","volume":"105","author":"O'Connor","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0405","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2014.08.033_bb0410","doi-asserted-by":"crossref","first-page":"129S","DOI":"10.2967\/jnumed.107.045914","article-title":"Molecular imaging of hypoxia","volume":"49","author":"Krohn","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0415","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0360-3016(98)00301-0","article-title":"Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection","volume":"42","author":"Zhang","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0420","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0360-3016(98)00300-9","article-title":"Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo","volume":"42","author":"Honess","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0425","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.semnuclmed.2007.07.001","article-title":"Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole","volume":"37","author":"Lee","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0430","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11864-012-0220-6","article-title":"Angiogenesis inhibitors in the treatment of epithelial ovarian cancer","volume":"14","author":"Han","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0435","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0440","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/1535-7163.MCT-10-0976","article-title":"Assessing the activity of cediranib, a VEGFR-2\/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family","volume":"10","author":"Brave","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0445","volume":"31","author":"du Bois","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0450","series-title":"Presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting; May 30\u2013June 3, 2014; Chicago, IL","article-title":"Genomic alterations in paired pretreatment (pre) and progression (prog) tumor samples from ovarian cancer patients (pts) treated with pazopanib (pazo) or placebo (plb)","author":"Heitz","year":"2014"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0455","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","article-title":"Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer","volume":"30","author":"Karlan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0460","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2014.08.033_bb0465","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.5008","article-title":"Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT)","volume":"29","author":"Buckanovich","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814012864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814012864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:36:19Z","timestamp":1758771379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814012864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0090825814012864"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.08.033","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}